Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.
GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.
Lifileucel heads up the list of upcoming US FDA catalysts.
The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.
Private company trial initiations stand out in the latest week’s disclosures.
A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.